Meet Achille Iolascon, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
I serve the EHA as chairman of the Study working group on “Red cells and iron” since June 2014.

Meet Gert Ossenkoppele, our Volunteer of the Month

Can you tell us what you do for EHA and when you started? How did you became a volunteer? Who helped/encouraged you to become one?
I am lucky to be one of the first members of the EHA (member number 34).…

Meet Gert Ossenkoppele, our Volunteer of the Month

Can you tell us what you do for EHA and when you started? How did you became a volunteer? Who helped/encouraged you to become one?
I am lucky to be one of the first members of the EHA (member number 34).…

Uptake of CAR T cell therapy in Europe

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Publication of EHA Annual General Meeting 2023 minutes

EHA impact video



 

The 2023 EHA Annual General Meeting (AGM) took place in Frankfurt, Germany on June 9, 2023.

Computational Biology Training in Hematology Hall of Fame

Clinical Research Training in Hematology Hall of Fame

Translational Research Training in Hematology Hall of Fame

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.